Posted by Michael Wonder on 13 Aug 2024
Enhertu approved in China for patients with previously treated HER2 positive advanced or metastatic gastric cancer
13 August 2024 - Approval based on DESTINY-Gastric06 results which showed Enhertu demonstrated clinically meaningful efficacy in this setting.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma who have received two or more prior treatment regimens.
